Abstract:The canine prostate appears to be a suitable model for investigating many aspects of abnormal prostate growth related to BPH. This model has indicated that BPH is a complex pathologic process that varies with age and produces a gland that is composed of a mixture of glandular, cystic, and stromal hyperplasia juxtapositioned with foci of atrophy. Canine BPH first occurs very early in life as a glandular hyperplasia before the onset of more complex BPH. As the prostate increases in size with age, the tissue dihydrotestosterone content falls, as does the secretory capacity of the gland. The fall in glandular dihydrotestosterone content is counterbalanced by a concomitant increase in the metabolism of androgens toward dihydrotestosterone and an increase in nuclear androgen receptors. As the prostate ages, it thus becomes more sensitive to androgens, which are required for maintaining the abnormal size of the gland. Established BPH can be maintained in the absence of the testes in the presence of normal testosterone levels, and it appears that the abnormal growth is primarily attributable to an inherent change that has occurred in the aged prostate. In the dog and man, both the normal prostate and BPH are rich in growth factors and dihydrotestosterone receptor in the nucleus, yet mitotic cells are rare. Established BPH is not growing rapidly; the abnormal size of the aged prostate is maintained, not by an increase in the rate of cell replication, but rather by an apparent decrease in the rate of cell death. It appears that a combination of estrogens and 5 alpha-reduced androgens can cause this decrease in the rate of cell death and replication and that this imbalance can produce abnormal cell accumulation and an experimental prostatic hyperplasia. Besides affecting cell death and replication, estradiol has a marked effect in stimulating the stroma and collagen synthesis. Current investigations are focusing on determining the distribution of stem cells for both the epithelial and the stromal elements of the prostate, how these stem cells are recruited to form transiently proliferating cells, and how they mature and subsequently are programmed for cell death. It is believed that steroid imprinting in the neonatal and prepubertal period may be of great importance in determining the ultimate growth of the prostate. Preliminary attempts to control abnormal canine prostate growth by forcing maturation with retinoic acid, or by interfering with growth factors through the use of suramin, have not proved effective; only androgen ablation is. Important leads in the search for the etiology and control of BPH can be studied in the canine model. These concepts must ultimately be tested and confirmed for human BPH in well-controlled clinical investigations.

Cuins2 Quantum Dots/Poly(L-Glutamic Acid)-Drug Conjugates for Drug Delivery and Cell Imaging

Translocation Mechanism of Anticancer Drugs Through Membrane with the Assistance of Graphene Quantum Dot

Duplex metal co-doped carbon quantum dots-based drug delivery system with intelligent adjustable size as adjuvant for synergistic cancer therapy

Synthesis Of Ternary Cuins2/Zns Quantum Dot Bioconjugates And Their Applications For Targeted Cancer Bioimaging

Dually Responsive Nanoparticles for Drug Delivery Based on Quaternized Chitosan

Doxorubicin-CdS Nanoparticles: A Potential Anticancer Agent for Enhancing the Drug Uptake of Cancer Cells

Practical Aspects of the Integration of Agile Development and Model-driven Development: An Exploratory Study

Clinical and experimental studies of benign prostatic hyperplasia.

In vivo cancer targeting and imaging with semiconductor quantum dots

SnoN in regulation of embryonic development and tissue morphogenesis

Cuins2/Zns Quantum Dots Conjugating Gd(Iii) Chelates for Near-Infrared Fluorescence and Magnetic Resonance Bimodal Imaging

Au:Cdhgte Quantum Dots for in Vivo Tumor-Targeted Multispectral Fluorescence Imaging

Facile Synthesis of Gd-Cu-In-S/ZnS Bimodal Quantum Dots with Optimized Properties for Tumor Targeted Fluorescence/MR In Vivo Imaging

N doped-carbon quantum dots with ultra-high quantum yield photoluminescent property conjugated with folic acid for targeted drug delivery and bioimaging applications

Black Phosphorus Quantum Dots Gated, Carbon-Coated Fe3 O4 Nanocapsules (BPQDs@ss-Fe3 O4 @C) with Low Premature Release Could Enable Imaging-Guided Cancer Combination Therapy

Fluorescent graphene quantum dots as traceable, pH-sensitive drug delivery systems

Fluorescent carbon quantum dots-based prodrug nanosponges with outstanding tumor-specific drug delivery and imaging

Co-delivery of Cu(I) Chelator and Chemotherapeutics As a New Strategy for Tumor Theranostic.

Graphene quantum dots coated cationic polymer for targeted drug delivery and imaging of breast cancer

Using host–guest interactions at the interface of quantum dots to load drug molecules for biocompatible, safe, and effective chemo-photodynamic therapy against cancer

In Vivo and in Situ Tracking Cancer Chemotherapy by Highly Photostable NIR Fluorescent Theranostic Prodrug